MedTrace Logo

A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer

NCT06200363 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-01-11

No results posted yet for this study

Summary

This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intravenous administration of T3011 at different doses in combination with oral regorafenib in the treatment of advanced colorectal cancer.

Conditions

  • Advanced Colorectal Cancer

Interventions

DRUG

T3011

T3011 will be administered intravenously on D1, 4, 8, 11, 15, 18 of each 28-day cycle.

DRUG

Regorafenib

Regorafenib will be administered orally once daily for the first 21 days of each 28-day cycle according to NCCN and CSCO guidance.

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06200363 on ClinicalTrials.gov